Vitamin D Prohormone in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Overview

Journal Int J Nephrol Renovasc Dis

Publisher Dove Medical Press

Specialty Nephrology

Date 2017 May 27

PMID 28546765

Citations 9

Authors

Claudia Friedl

Emanuel Zitt

Affiliations

Soon will be listed here.

Abstract

Secondary hyperparathyroidism (sHPT) represents the adaptive and very often, finally, maladaptive response of the organism to control the disturbed homeostasis of calcium, phosphorus, and vitamin D metabolism caused by declining renal function in chronic kidney disease (CKD). sHPT leads to cardiovascular and extravascular calcifications and is directly linked to an increased risk of cardiovascular morbidity and mortality as well as excess all-cause mortality. Vitamin D plays an important role in the development of sHPT. CKD patients are characterized by a high prevalence of hypovitaminosis D. Supplementation with both vitamin D prohormones cholecalciferol and ergocalciferol enables the achievement and maintenance of a normal vitamin D status when given in adequate doses over an appropriate treatment period. In patients with earlier stages of CKD, sHPT is influenced by and can be successfully treated with vitamin D prohormone supplementation, whereas in patients with very late stages of CKD and those requiring dialysis, treatment with prohormones seems to be of limited efficacy. This review gives an overview of the pathogenesis of sHPT, summarizes vitamin D metabolism, and discusses the existing literature regarding the role of vitamin D prohormone in the treatment of sHPT in patients with CKD.

Citing Articles

Hemodialysis Patients May Benefit from Cholecalciferol Treatment Targeting High Level of 25(OH)D.

Tarasewicz A, Dabrowska M, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Malgorzewicz S Medicina (Kaunas). 2024; 60(11).

PMID: 39597015 PMC: 11596388. DOI: 10.3390/medicina60111831.

The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients.

Tarasewicz A, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Malgorzewicz S, Jankowska M Biomedicines. 2024; 12(2).

PMID: 38397979 PMC: 10886943. DOI: 10.3390/biomedicines12020377.

The effects and safety of high dose vitamin D3 in hemodialysis patients.

Guella A, Abduelkarem A, Hassanein M Pharm Pract (Granada). 2023; 21(1):2773.

PMID: 37090466 PMC: 10117363. DOI: 10.18549/PharmPract.2023.1.2773.

The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease.

Pistis K, Westerberg P, Qureshi A, Beshara S, Sterner G, Barany P BMC Nephrol. 2023; 24(1):20.

PMID: 36698076 PMC: 9875529. DOI: 10.1186/s12882-022-03014-z.

[Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian...].

Cejka D, Wakolbinger-Habel R, Zitt E, Fahrleitner-Pammer A, Amrein K, Dimai H Wien Med Wochenschr. 2022; 173(13-14):299-318.

PMID: 36542221 PMC: 10516794. DOI: 10.1007/s10354-022-00989-0.

References

Pavik I, Jaeger P, Ebner L, Wagner C, Petzold K, Spichtig D . Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant. 2012; 28(2):352-9. DOI: 10.1093/ndt/gfs460. View

Susantitaphong P, Nakwan S, Peerapornratana S, Tiranathanagul K, Katavetin P, Srisawat N . A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria. BMC Nephrol. 2017; 18(1):19. PMC: 5237567. DOI: 10.1186/s12882-017-0436-6. View

Mose F, Vase H, Larsen T, Kancir A, Kosierkiewic R, Jonczy B . Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial. BMC Nephrol. 2014; 15:50. PMC: 3994388. DOI: 10.1186/1471-2369-15-50. View

Halloran B, Schaefer P, Lifschitz M, Levens M, GOLDSMITH R . Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J Clin Endocrinol Metab. 1984; 59(6):1063-9. DOI: 10.1210/jcem-59-6-1063. View

Hewitt N, OConnor A, OShaughnessy D, Elder G . Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol. 2013; 8(7):1143-9. PMC: 3700687. DOI: 10.2215/CJN.02840312. View

Bouillon R, Verlinden L, Verstuyf A . Is Vitamin D2 Really Bioequivalent to Vitamin D3?. Endocrinology. 2016; 157(9):3384-7. DOI: 10.1210/en.2016-1528. View

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

Fan Y, Bi R, Densmore M, Sato T, Kobayashi T, Yuan Q . Parathyroid hormone 1 receptor is essential to induce FGF23 production and maintain systemic mineral ion homeostasis. FASEB J. 2015; 30(1):428-40. PMC: 4684518. DOI: 10.1096/fj.15-278184. View

Zisman A, Hristova M, Ho L, Sprague S . Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43. DOI: 10.1159/000098561. View

10.

Chandra P, Binongo J, Ziegler T, Schlanger L, Wang W, Someren J . Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008; 14(1):10-7. PMC: 2654595. DOI: 10.4158/EP.14.1.10. View

11.

Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D . Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2008; 24(5):1506-23. DOI: 10.1093/ndt/gfn613. View

12.

Fraser D, KODICEK E . Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970; 228(5273):764-6. DOI: 10.1038/228764a0. View

13.

Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J . An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999; 96(4):507-15. DOI: 10.1016/s0092-8674(00)80655-8. View

14.

Holick M . Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004; 80(6 Suppl):1678S-88S. DOI: 10.1093/ajcn/80.6.1678S. View

15.

Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H . Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail. 2008; 30(4):407-10. DOI: 10.1080/08860220801964210. View

16.

Moe S, Saifullah A, LaClair R, Usman S, Yu Z . A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5(2):299-306. PMC: 2827596. DOI: 10.2215/CJN.07131009. View

17.

Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T . Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol. 2012; 16(5):722-9. DOI: 10.1007/s10157-012-0621-7. View

18.

Zitt E, Sprenger-Mahr H, Mundle M, Lhotta K . Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency. BMC Nephrol. 2015; 16:128. PMC: 4523023. DOI: 10.1186/s12882-015-0116-3. View

19.

Henry H . Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):531-41. DOI: 10.1016/j.beem.2011.05.003. View

20.

Armas L, Hollis B, Heaney R . Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004; 89(11):5387-91. DOI: 10.1210/jc.2004-0360. View